Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference

Hepato-Gastroenterology

Volumn 59, Issue 119, 2012, Pages 2238-2242

  Li, Hongyang ^a   Zhou, Shiji ^a   Li, Tao ^a   Liu, Zuojin ^a   Wu, Jinfeng ^a   Zeng, Guili ^a   Liu, Changan ^a   Gong, Jianping ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer resistance; Hepatocellular carcinoma.; Multidrug resistance; RNA interference

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DOXORUBICIN; MESSENGER RNA; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANTIBIOTICS, ANTINEOPLASTIC; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LIVER NEOPLASMS; NEOPLASM PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; TRANSFECTION;

EID: 84872085481     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11781     Document Type: Article

References (34)

1. Cindric M, Cipak A, Serly J, et al.: Reversal of multidrug resistance in murine lymphoma cells by amphiphilic dihydropyridine antioxidant derivative. Anticancer Res 2010; 30(10):40 63-4069.
2. Gaopeng Li,Xiaoping Chen,Lu Ye, et al.: An research of the effect and the mechanism of breast cancer resistance protein (BCRP) on multidrug resistance in hepatic cellular carcinoma. Abdom Sur 2006; 19(5):301-303.
3. Donze O, Picard D: RNA interference in mammalian cells using SiRNAs synthesized with T7 RNA polymerase. Nucleic Acids Res 2002; 30(10):e46.
4. Rachel Ee, Xiaolong He, Douglas D, et al.: Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. Mol Cancer Ther 2004; 3(12):1577-1583.
5. Li WT, Zhou GY, Song XR, et al.: Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference. Neoplasma 2005; 52:219-224.
6. Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering rnas in mammalian cells. Science 2002; 296(5567):550-553.
7. Wang Ning, Li Yu, Liu Jie: Establishment of a multidrug resistance cell line of human hepatic carcinoma HepG2/ADM with Adriamycin and the expression analysis of multidrug resistance-associated gene.Chin J Lab Dign 2006; 10(5):460-463.
8. Kawabata S, Oka M, Shiozawa K, et al.: Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 2001; 280:1216-1223.
9. Berridge MV, Tan AS: Characterization of the cellular reduction of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys1993; 303:474-482.
10. Chearwae W, Anuchapreeda S, Nandigama K, et al.: Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from turmeric powder. Biochem Pharmacol 2004; 68:2043-2052.
11. Chearwae W, Wu CP, Chu HY, Lee TR, et al.: Curcuminoids purified from turmeric powder modulates the function of human multidrug resistance protein 1 (ABCC1). Cancer Chemother Pharmacol 2005; 57:376-388.
12. Wu CP, Calcagno AM, Hladky SB, et al.: Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). Febs J 2005; 272:4725-4740.
13. Ifergan I, Shafran A, Jansen G, et al.: Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J Biol Chem 2004; 279:25527-25534.
14. Calcagno AM, Fostel JM, Kenneth KWT, et al.: Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. Br J Cancer; 98(9):1515-1524.
15. Faneyte IF, Kristel PM, Maliepaard M, et al.: Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res 2002; 8:1068-1074.
16. Burger H, Foekens JA, Look MP, et al.: RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance- associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 2003; 9:827-836.
17. Schneiderman RS, Shmueli E, Kirson ED, et al.: TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sublines that overexpress ABC transporters. BMC Cancer 2010; 10:229.
18. Ma Y, Wink M: The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res 2010; 24(1):146-149.
19. Xiaoweng H, Rui H: Progress of drug resistant protein of breast cancer, Int Surg J 2006; 33:131-147.
20. Sarkadi B, Ozvegy-Laczka C, Nemet K, et al.: ABCG2: A transporter for all seasons. FEBS Lett 2004; 567:116-120.
21. Staud F, Pavek P: Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol 2005; 37:720-725.
22. Minotti G, Menna P, Salvatorelli E, et al.: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56:185-229.
23. Vander Borght S, Komuta M, Libbrecht L, et al.: Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int 2008; 28(10):1370-1380.
24. Ni Z, Bikadi Z, Cai X, et al.: Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport. Am J Physiol Cell Physiol 2010; 299(5):C1100-1109.
25. Li G, Chen X, Wang Q, et al.: The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance. J Huazhong Univ Sci Technolog Med Sci 2007; 27(2):173-175.
26. Sumimoto H, Yamagata S, Shimizu A, et al.: Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther 2005; 12(1):95-100.
27. Xu D, Kang H, Fisher M, et al.: Strategies for inhibition of MDR1 gene expression. Mol Pharmcol 2004; 66(2):268-275.
28. Stege A, Priebsch A, Nieth C, et al.: Stable and complete overcoming of MDR1/P- glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther 2004; 11:699-706.
29. Yagüe E, Higgins CF, Raguz S: Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene Ther 2004; 11:1170-1174.
30. Kowalski P, Stein U, Scheffer GL, et al.: Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther 2002; 9:579-586.
31. Dai DJ, Lu CD, Guo JM, et al.: Effect of inhibiting survivin expression with antisense oligodeoxynucleotides on sensitivity of hepatocellular carcinoma cell lines HepG2 and HepG2/ADM to Adriamycin. Ai Zheng 2005; 24(8):951-957.
32. Lv H, He Z, Liu X, et al.: Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs. J Cell Biochem 2007; 102(1):75-81.
33. Tao P, Zhang J, Tang N, et al.: Potent and specific inhibition of SARS-CoV antigen expression by RNA interference. Chin Med J 2005; 118:714-719.
34. Shrey K, Suchit A, Nishant M, et al.: RNA interference: emerging diagnostics and therapeutics tool. Biochem Biophys Res Commun 2009; 386(2):273-277.